Pei Shu

2.4k total citations · 1 hit paper
37 papers, 1.4k citations indexed

About

Pei Shu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Pei Shu has authored 37 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 10 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Pei Shu's work include Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (5 papers) and CAR-T cell therapy research (5 papers). Pei Shu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (5 papers) and CAR-T cell therapy research (5 papers). Pei Shu collaborates with scholars based in China, United States and Singapore. Pei Shu's co-authors include Yongsheng Wang, Benxia Zhang, Qizhi Ma, Kai Li, Yue Chen, Dan Li, Xuejin Ou, Houhui Shi, Karen J. Moore and John S. Smutko and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and Scientific Reports.

In The Last Decade

Pei Shu

32 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

2021 581 citations Kai Li, Benxia Zhang et al. Signal Transduction and Targeted Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pei Shu China	12	559	528	499	236	168	37	1.4k
Huafeng Wei China	27	974 1.7×	672 1.3×	819 1.6×	130 0.6×	135 0.8×	57	2.1k
Matthew R. Farren United States	19	482 0.9×	396 0.8×	625 1.3×	101 0.4×	82 0.5×	34	1.3k
Yingxi Xu China	24	570 1.0×	943 1.8×	879 1.8×	191 0.8×	97 0.6×	77	2.0k
Bence Dániel United States	20	722 1.3×	775 1.5×	359 0.7×	118 0.5×	76 0.5×	41	1.5k
Kyungho Choi South Korea	22	627 1.1×	472 0.9×	498 1.0×	92 0.4×	92 0.5×	54	1.5k
Stefan Siwko United States	26	242 0.4×	1.2k 2.2×	696 1.4×	201 0.9×	104 0.6×	43	1.8k
Shuji Kubo Japan	22	231 0.4×	768 1.5×	260 0.5×	304 1.3×	99 0.6×	68	1.8k
Bhagelu R. Achyut United States	25	705 1.3×	766 1.5×	624 1.3×	84 0.4×	250 1.5×	58	1.9k
Florian Halbritter Austria	18	588 1.1×	1.3k 2.5×	179 0.4×	136 0.6×	129 0.8×	33	2.0k
Caitlin B. Conboy United States	11	215 0.4×	811 1.5×	264 0.5×	184 0.8×	203 1.2×	23	1.3k

Countries citing papers authored by Pei Shu

Since Specialization

Citations

This map shows the geographic impact of Pei Shu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pei Shu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pei Shu more than expected).

Fields of papers citing papers by Pei Shu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pei Shu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pei Shu. The network helps show where Pei Shu may publish in the future.

Co-authorship network of co-authors of Pei Shu

This figure shows the co-authorship network connecting the top 25 collaborators of Pei Shu. A scholar is included among the top collaborators of Pei Shu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pei Shu. Pei Shu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shu, Pei, Xiaoyu Li, Qi Zhou, et al.. (2025). Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors. Signal Transduction and Targeted Therapy. 10(1). 198–198.

Shu, Pei, Fang Wang, & Xin Wang. (2025). Case Report: Abscopal effect in a patient with refractory metastatic hepatocellular carcinoma treated with stereotactic body radiotherapy and PD-1 inhibitor. Frontiers in Immunology. 16. 1536689–1536689.

Shu, Pei, Xin Wang, Jitao Zhou, et al.. (2024). Comparison of Survival Between Different Histological Subtypes in Cervical Cancer Patients: A Retrospective and Propensity Score-matched Analysis. Journal of Cancer. 15(19). 6326–6335. 1 indexed citations

Li, Yuan, Pei Shu, Xiaoyu Li, et al.. (2024). A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort.. Journal of Clinical Oncology. 42(16_suppl). 5509–5509. 2 indexed citations

Qin, Diyuan, et al.. (2024). Targeting tumor-infiltrating tregs for improved antitumor responses. Frontiers in Immunology. 15. 1325946–1325946. 23 indexed citations

Shu, Pei, Ning Liu, Xu Luo, et al.. (2024). An immune-related gene prognostic prediction risk model for neoadjuvant chemoradiotherapy in rectal cancer using artificial intelligence. Frontiers in Oncology. 14. 1294440–1294440. 2 indexed citations

Zhou, Kexun, Pei Shu, Hanrui Zheng, & Qiu Li. (2023). Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective. Frontiers in Pharmacology. 14. 1133085–1133085. 2 indexed citations

Li, Xiaoyu, Pei Shu, Diyuan Qin, et al.. (2023). First-in-human, phase I study of KC1036, a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). e15000–e15000. 1 indexed citations

Gao, Ge, Wei‐Ting Liao, Pei Shu, et al.. (2023). Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor. Journal for ImmunoTherapy of Cancer. 11(8). e006343–e006343. 17 indexed citations

10.

Ma, Qizhi, Pei Shu, Kexun Zhou, & Yongsheng Wang. (2023). Case Report: Termination of unplanned pregnancy led to rapid deterioration of non-small-cell lung cancer during osimertinib treatment. Frontiers in Oncology. 13. 1073938–1073938.

11.

Yang, Ling, et al.. (2023). Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198, a novel, selective Autotaxin inhibitor, in healthy subjects: A phase I randomized placebo-controlled trial. European Journal of Pharmaceutical Sciences. 189. 106552–106552. 3 indexed citations

12.

Zhang, Benxia, Min Hu, Qizhi Ma, et al.. (2023). Optimized CAR-T therapy based on spatiotemporal changes and chemotactic mechanisms of MDSCs induced by hypofractionated radiotherapy. Molecular Therapy. 31(7). 2105–2119. 19 indexed citations

13.

Zhang, Benxia, Xue Li, Tao Yin, et al.. (2022). Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention. Journal of Oncology. 2022. 1–12. 2 indexed citations

14.

Yang, Xibiao, Xiangbing Deng, Wenjian Meng, et al.. (2021). Predicting Response to Total Neoadjuvant Treatment (TNT) in Locally Advanced Rectal Cancer Based on Multiparametric Magnetic Resonance Imaging: A Retrospective Study. Cancer Management and Research. Volume 13. 5657–5669. 6 indexed citations

15.

Wu, Xiaohua, Xiaoxuan Zhang, Pei Shu, et al.. (2020). A39 Reactive Cutaneous Capillary Endothelial Proliferation Caused by Camrelizumab (SHR-1210) Through Activation of HIF-1α/VEGF Signaling Pathway. Journal of Thoracic Oncology. 15(2). S25–S26. 2 indexed citations

16.

Li, Xiaoyu, Youling Gong, Dan Li, et al.. (2020). Low-Dose Radiation Therapy Promotes Radiation Pneumonitis by Activating NLRP3 Inflammasome. International Journal of Radiation Oncology*Biology*Physics. 107(4). 804–814. 42 indexed citations

17.

Jiang, Li, Fuchun Guo, Xiaoyu Li, et al.. (2019). Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC. Scientific Reports. 9(1). 3705–3705. 36 indexed citations

18.

Wang, Xin, Yaqin Zhao, Yali Shen, et al.. (2015). Long-term follow-up results of simultaneous integrated or late course accelerated boost with external beam radiotherapy to vaginal cuff for high risk cervical cancer patients after radical hysterectomy. BMC Cancer. 15(1). 257–257. 5 indexed citations

19.

Khoury, Jane, et al.. (2008). Eye Position Information on CT Increases the Identification of Acute Ischemic Hypoattenuation. American Journal of Neuroradiology. 29(6). 1144–1146. 15 indexed citations

20.

Rivera, Jaime A., Christopher Rall, Fiona Graeme‐Cook, et al.. (1997). Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia. Surgery. 121(1). 42–49. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact